Aprilbio Co., Ltd.

As of June 30, 2026, Aprilbio Co., Ltd. carries a market capitalization of 946.54B, placing it among publicly traded companies globally. Its enterprise value stands at 866.35B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Aprilbio Co., Ltd. has 23.34M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Aprilbio Co., Ltd. maintains a current ratio of 67.70, meaning it holds 67.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 0.55, indicating moderate leverage, while an interest coverage ratio of -36.09 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Aprilbio Co., Ltd. posted a negative return on equity (ROE) of -9.65, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -9.22, reflecting losses generated across the asset base.

As of the close on October 23, 2026, Aprilbio Co., Ltd.'s stock has declined approximately 55.73% over the past 52 weeks. The 50-day moving average sits at 18,534.00, while the 200-day moving average is 43,071.45.

These figures cover the twelve months ended June 30, 2026. EBITDA reached -8.95B, while operating income came in at -9.60B.

As of June 30, 2026, Aprilbio Co., Ltd. holds 80.73B in cash and equivalents against 530.33M in total debt, resulting in a net debt position of -7.44B. Total book value stands at 96.88B, with working capital of 81.71B providing operational flexibility.

Aprilbio Co., Ltd. produced -4.67B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -778.26M in capital expenditures, free cash flow totaled -5.45B - equivalent to -235.70 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -0.58: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.31, meaning Aprilbio Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Aprilbio Co., Ltd.'s most recent stock split took place on October 31, 2023 with a 1:2 split ratio.